ARS Pharmaceuticals, Inc (SPRY)
Healthcare
Biotechnology
—
5.10 $
-8.9%
vs. previous close
Closing price · As of: 31. Jul 2026
ARS Pharmaceuticals, Inc (SPRY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -45 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17 | -13 | -17 | -6.7 | -7.3 | -14 | 42 | -41 | -40 | -47 | -43 | -45 | -175 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5 | -1.7 | 0.3 | 2.4 | -1.5 | 0.4 | 1.5 | |
| 2.1 | 2.6 | 2.3 | 3.3 | 3.4 | 3.6 | 4.3 | 5.3 | 5.4 | 5.7 | 5.7 | 7.4 | 24 | |
| 2.1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.3 | 1.0 | -11 | 2.2 | 3.8 | -1.5 | -11 | -10 | -1.1 | -1.1 | -7.5 | 8.6 | -1.0 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.3 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | |
| 45 | -47 | 26 | -8.5 | -13 | 17 | -102 | 29 | 49 | -45 | 24 | 28 | 55 | |
| 2.9 | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -0.7 | – | – | |
| 2.9 | 0.9 | 1.8 | 0.3 | 0.5 | 0.7 | 71 | 0.7 | 2.7 | 100 | 1.1 | 0.2 | 104 | |
| 31 | -58 | 10 | -15 | -19 | 3.0 | 11 | -11 | 12 | 8.0 | -18 | -17 | -16 | |
| -17 | -13 | -17 | -6.8 | -7.3 | -15 | 42 | -41 | -40 | -47 | -43 | -45 | -175 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.